第1選択および第2選択の化学療法を受けた進行非小細胞肺がん患者のQOL-無作為化比較試験のメタアナリシス-

概要

論文の詳細を見る
Objective: For advanced non-small-cell lung cancer (NSCLC) patients, the only treatment option is the palliative therapy, with the aim of prolonging overall survival and improving disease-related symptoms and quality of life (QOL). However, there has been no meta-analysis of previous studies reporting QOL outcomes following such a palliative treatment. We consider that it is important to evaluate not only survival and/or response rates, but also the QOL of patients with advanced NSCLC receiving palliative chemotherapy. It is also important to assess the QOL of advanced NSCLC patients from first-line to second-line treatment. Method: We performed a systematic review and a meta-analysis of QOL outcomes following each of the effects of first-line and second-line treatment for advanced NSCLC patients. Results: Global QOL was significantly different between the treatments during first-line and second-line treatment, while the survival rate that was the primary outcome in clinical trials was not significantly different between the treatments. Conclusions: The number of trials of treatments of advanced NSCLC has increased, especially when the main objective is to avoid disease progression. If QOL assessments are performed and QOL is included as a treatment outcome, patients will gain useful information in selecting suitable chemotherapy regimens that take QOL into consideration.
2011-10-00